Olga Maltseva Portfolio
Invests via Catalio Capital Management LP | Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Invests via Catalio Capital Management LP
Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Automatically Tracked
Olga Maltseva Profile
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Investment Philosophy & Strategy
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
63.02%
Gain -2.45%
Monthly
2.43%
Yearly
33.46%
Drawdown
20.67%
$534.1M
Equity
Holdings
$534.1M
Investment
$462.22M
$248.81M
Profit -$13.2M
Realized
$176.94M
Unrealized
$71.87M
Dividends
$3.07M
Goals
Avg. 71.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-2.45%
Profit
-$13.2M
Win %
58%
This Week
Compared To Last Week
Gain
-5.47%
Profit
-$30.88M
Win %
58%
This Month
Compared to last month
Gain
-4.56%
Profit
-$25.52M
Win %
58%
This Year
Compared to last year
Gain
2.16%
Profit
$11.31M
Win %
61%
FTH Faeth Therapeutics, Inc.
+7.97%
+$42,387.84 
MGX Metagenomi, Inc.
+0.87%
+$5,289.93 
ATAI AtaiBeckley Inc.
+0.82%
+$11,811.48 
EW Edwards Lifesciences Corporation
+0.67%
+$72,371.24 
RARE Ultragenyx Pharmaceutical Inc.
+0.63%
+$28,462.68 
GUTS Fractyl Health Inc.
+0.48%
+$19,123.12 
KLRA Kailera Therapeutics, Inc.
+0.47%
+$32,812.5 
AXSM Axsome Therapeutics, Inc.
+0.23%
+$20,943.27 
ASND Ascendis Pharma A/S
+0.16%
+$13,338.78 
PTGX Protagonist Therapeutics Inc.
+0.05%
+$7,475.93 
BBOT BridgeBio Oncology Therapeutics, Inc.
-18.28%
-$393,232.65 
PBLS Parabilis Medicines, Inc.
-6.29%
-$2.01M 
SNDX Syndax Pharmaceuticals Inc.
-5.14%
-$1.24M 
KARD Kardigan, Inc.
-5.03%
-$309,375 
FDMT 4D Molecular Therapeutics, Inc.
-4.87%
-$325,165.26 
BBIO BridgeBio Pharma, Inc.
-4.71%
-$1.63M 
KPTI Karyopharm Therapeutics Inc.
-4.14%
-$65,859.85 
GPCR Structure Therapeutics Inc.
-4.08%
-$464,604 
DYN Dyne Therapeutics Inc.
-4.01%
-$188,595.33 
MLYS Mineralys Therapeutics, Inc.
-3.93%
-$778,466.4 
ODTX Odyssey Therapeutics, Inc.
-3.55%
-$398,319.93 
DNTH Dianthus Therapeutics Inc.
-3.51%
-$123,858.16 
AVLN Avalyn Pharma Inc.
-3.37%
-$2.03M 
IRON Disc Medicine Inc.
-3.1%
-$377,740.08 
CRVS Corvus Pharmaceuticals Inc.
-2.93%
-$421,546.32 
IMCR Immunocore Holdings plc American Depositary Receipt
-2.58%
-$131,760.05 
HTFL HeartFlow, Inc.
-2.53%
-$688,004.9 
INCY Incyte Corporation
-2.17%
-$523,141.71 
ELDN Eledon Pharmaceuticals Inc.
-1.42%
-$67,802.84 
NTRA NATERA INC (Common Stock) – ticker 45E
-1.26%
-$342,694.77 
MANE Veradermics Inc.
-1.22%
-$55,944.32 
OM Outset Medical Inc.
-1.21%
-$4,731.16 
TARA Protara Therapeutics Inc.
-1.04%
-$20,805.92 
BMY Bristol-Myers Squibb Company
-1.03%
-$274,619.07 
DFTX Definium Therapeutics, Inc.
-0.68%
-$146,294.72 
SEPN Septarna Inc.
-0.58%
-$117,953.44 
GILD Gilead Sciences Inc.
-0.58%
-$226,219.56 
HYPR Hyperfine Inc.
-0.57%
-$5,940.18 
JNJ Johnson & Johnson
-0.27%
-$98,651.66 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 233 | Longs Won 140/233 60% | Profit Factor 3.15 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4.11M |
| Average Win $2.61M | Best Trade (Jun 30) $39.91M | Sharpe Ratio -160.1 |
| Average Loss -$1.25M | Worst Trade (Jun 29) -$12.52M | Z-Score -0.45 (34.46%) |
| Commissions $0 | Avg. Trade Length 6m 4w 1d | Expectancy $1.07M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.08% |
| Consecutive Losing Trades | 429 | 386 | 343 | 300 | 257 | 214 | 171 | 129 | 86 | 43 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S | 31,759 | $8.47M | $8.3M | - | -$174,356.43 | -2.06% | +0.161% |
| ATAI AtaiBeckley Inc. | 196,858 | $696,877.01 | $1.45M | - | $750,029.29 | 107.63% | +0.823% |
| AVLN Avalyn Pharma Inc. | 1.68M | $48.57M | $58.1M | - | $9.54M | 19.63% | -3.372% |
| AXSM Axsome Therapeutics, Inc. | 43,182 | $10.57M | $9.12M | - | -$1.45M | -13.75% | +0.23% |
| BBIO BridgeBio Pharma, Inc. | 455,041 | $33.8M | $32.99M | - | -$805,938.46 | -2.38% | -4.706% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 318,407 | $2.43M | $1.76M | - | -$668,654.35 | -27.56% | -18.283% |
| BMY Bristol-Myers Squibb Company | 412,961 | $22.28M | $26.32M | - | $4.05M | 18.18% | -1.032% |
| CRVS Corvus Pharmaceuticals Inc. | 1.08M | $15.87M | $13.99M | - | -$1.89M | -11.88% | -2.926% |
| DFTX Definium Therapeutics, Inc. | 562,672 | $10.63M | $21.23M | - | $10.6M | 99.63% | -0.684% |
| DNTH Dianthus Therapeutics Inc. | 32,941 | $718,113.81 | $3.4M | - | $2.68M | 373.76% | -3.513% |
| DYN Dyne Therapeutics Inc. | 244,929 | $4.79M | $4.51M | - | -$279,218.86 | -5.83% | -4.013% |
| ELDN Eledon Pharmaceuticals Inc. | 1.7M | $4.44M | $4.71M | - | $275,854.24 | 6.22% | -1.418% |
| EW Edwards Lifesciences Corporation | 124,778 | $10.64M | $10.83M | - | $188,414.78 | 1.77% | +0.673% |
| FDMT 4D Molecular Therapeutics, Inc. | 471,254 | $5.43M | $6.36M | - | $928,370.38 | 17.1% | -4.866% |
| FTH Faeth Therapeutics, Inc. | 14,718 | $126,280 | $574,002 | - | $447,722 | 354.55% | +7.973% |
| GILD Gilead Sciences Inc. | 269,309 | $33.43M | $39M | - | $5.56M | 16.64% | -0.577% |
| GPCR Structure Therapeutics Inc. | 276,550 | $6.79M | $10.94M | - | $4.15M | 61.19% | -4.075% |
| GUTS Fractyl Health Inc. | 6.17M | $9.59M | $3.97M | - | -$5.62M | -58.63% | +0.484% |
| HTFL HeartFlow, Inc. | 583,055 | $15.63M | $26.52M | - | $10.89M | 69.65% | -2.528% |
| HYPR Hyperfine Inc. | 1.32M | $1.22M | $1.04M | - | -$186,661.13 | -15.24% | -0.569% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Olga Maltseva?
The largest contributions to the portfolio's profits come from the following stocks: Dianthus Therapeutics Inc - $47.31M, BridgeBio Pharma, Inc - $22.82M, Structure Therapeutics Inc - $16.72M, Eli Lilly and Company - $16.14M, and Ascendis Pharma A/S - $15.85M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Soleno Therapeutics, Inc - $18.18M, Boston Scientific Corporation - $13.75M, Septarna Inc - $9M, MoonLake Immunotherapeutics - $5.58M, and Veracyte Inc - $4.88M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Olga Maltseva's portfolio generate?
The portfolio generates substantial dividend income, with a total of $3.07M earned over time. The largest contributors to dividend income include Bristol-Myers Squibb Company - $1.24M, Gilead Sciences Inc - $550,869.19, Becton, Dickinson and Company - $366,683.2, Johnson & Johnson - $343,279.64, and AbbVie Inc - $253,927.76. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Olga Maltseva's monthly returns?
Olga Maltseva's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Olga Maltseva's strategy be considered aggressive or moderate?
Olga Maltseva's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Olga Maltseva's strategy?
Olga Maltseva's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
